Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 2/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.30 |
| ▸ | PAK4 | O96013 | 2/20 | 0.30 |
| ▸ | ABL1 | P00519 | 2/20 | 0.30 |
| ▸ | FYN | P06241 | 2/20 | 0.30 |
| ▸ | RET | P07949 | 2/20 | 0.30 |
| ▸ | KDR | P35968 | 2/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.30 |
| ▸ | CDK8 | P49336 | 2/20 | 0.30 |
| ▸ | GSK3A | P49840 | 2/20 | 0.30 |
| ▸ | GSK3B | P49841 | 2/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.30 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
| ▸ | PLK4 | O00444 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6788430 | 0.79 | RECQL (0.31) | — | |
| SCHEMBL19852947 | 0.78 | NOS2 (0.41) | NOS3NOS2NOS1 | |
| SCHEMBL12893310 | 0.77 | NOS3 (0.39) | NOS3NOS2NOS1AURKAMAP4K4 | |
| SCHEMBL580789 | 0.76 | TAAR1 (0.36) | — | |
| SCHEMBL2897887 | 0.76 | — | — | |
| SCHEMBL18398216 | 0.75 | NOS2 (0.47) | NOS3NOS2NOS1 | |
| SCHEMBL22863922 | 0.75 | NOS3 (0.38) | NOS3NOS2NOS1 | |
| SCHEMBL2897857 | 0.75 | — | — | |
| SCHEMBL6789137 | 0.75 | CCNB2 (0.35) | GSK3AGSK3BCDK1CDK5 | |
| SCHEMBL581364 | 0.75 | CCNB2 (0.35) | GSK3AGSK3BCDK1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| EP-4093400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | The Trustees of Princeton University (US) | 2022-11-30 | — | — | EP | disclosed |
| WO-2021151062-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERISTY (US) | 2021-07-29 | — | — | WO | disclosed |
| US-9522920-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140371206-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8796261-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| CN-101790517-B | Suppression of S1P1Bound material | TAISHO PHARMACEUTICAL CO LTD | 2013-08-21 | — | — | CN | disclosed |
| US-20120157428-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| EP-2177512-B1 | INHIBITOR OF BINDING OF S1P1 | TAISHO PHARMACEUTICAL CO LTD (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-8048898-B2 | Inhibitor of binding of S1P1 | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-11-01 | — | — | US | disclosed |
| US-8048898-B2 | Inhibitor of binding of S1P1 | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-11-01 | — | — | US | disclosed |
| US-8048898-B2 | Inhibitor of binding of S1P1 | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20100234594-A1 | INHIBITOR OF BINDING OF S1P1 | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234594-A1 | INHIBITOR OF BINDING OF S1P1 | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234594-A1 | INHIBITOR OF BINDING OF S1P1 | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-16 | — | — | US | disclosed |
| CN-101790517-A | Suppression of S1P1Bound material | TAISHO PHARMACEUTICAL CO LTD | 2010-07-28 | — | — | CN | disclosed |
| EP-2177512-A1 | INHIBITOR OF BINDING OF S1P1 | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157428-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | NOS3 4268/4885NOS2 4424/4885NOS1 4569/4885 |
| US-20100234594-A1 | INHIBITOR OF BINDING OF S1P1 | S1PR1, S1PR3, EDNRB | NOS3 212/4885NOS2 643/4885NOS1 162/4885 |
| US-20140371206-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | NOS3 4268/4885NOS2 4424/4885NOS1 4569/4885 |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PAH, ALDH2, IDH2 | NOS3 230/4885NOS2 123/4885NOS1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.